Literature DB >> 10979124

Viral RNA in middle ear mucosa and exudates in patients with chronic otitis media with effusion.

E Moyse1, M Lyon, G Cordier, J F Mornex, L Collet, P Froehlich.   

Abstract

OBJECTIVE: To evaluate viral and cytokine signaling correlates of the persistent inflammation associated with chronic otitis media with effusion (OME).
DESIGN: Prospective study.
METHOD: Reverse transcriptase-polymerase chain reaction targeting RNA viruses frequently associated with OME (respiratory syncytial virus and parainfluenza virus type 3, the proinflammatory cytokines interleukin 8 and interleukin 1beta, and RANTES [regulated upon activation, normal T cell expressed and secreted]) was performed on mucosal biopsy samples and on samples of the liquid and cellular compartments of inflammatory exudates obtained from 26 children (49 ears) with infected middle ears. Ribonucleic acid extracted from rapidly frozen samples was reverse transcribed by Moloney murine leukemia virus reverse transcriptase and amplified for 35 cycles using previously validated primers. Amplicons were evaluated by molecular size after agarose gel electrophoresis with ethidium bromide.
RESULTS: Most children had evidence of the presence of an RNA virus in at least one specimen. Respiratory syncytial virus was present in 40% and parainfluenza virus type 3 in 8% of effusions. Interleukin 8 messenger RNA was present in 21% of inflammatory exudates but never in cells from the mucosal biopsy samples.
CONCLUSIONS: Our data support a viral contribution to the cause of OME and suggest that the inflammatory cytokines observed derive more from cells in the inflammatory exudate than from those in the middle ear mucosa.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10979124     DOI: 10.1001/archotol.126.9.1105

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  8 in total

Review 1.  Antibiotic theory in otitis media.

Authors:  A Gungor; C D Bluestone
Journal:  Curr Allergy Asthma Rep       Date:  2001-07       Impact factor: 4.806

2.  Orally active fusion inhibitor of respiratory syncytial virus.

Authors:  Christopher Cianci; Kuo-Long Yu; Keith Combrink; Ny Sin; Bradley Pearce; Alan Wang; Rita Civiello; Stacey Voss; Guangxiang Luo; Kathy Kadow; Eugene V Genovesi; Brian Venables; Hatice Gulgeze; Ashok Trehan; Jennifer James; Lucinda Lamb; Ivette Medina; Julia Roach; Zheng Yang; Lisa Zadjura; Richard Colonno; Junius Clark; Nicholas Meanwell; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

3.  The pathogens profile in children with otitis media with effusion and adenoid hypertrophy.

Authors:  G P Buzatto; E Tamashiro; J L Proenca-Modena; T H Saturno; M C Prates; T B Gagliardi; L R Carenzi; E T Massuda; M A Hyppolito; F C P Valera; E Arruda; W T Anselmo-Lima
Journal:  PLoS One       Date:  2017-02-23       Impact factor: 3.240

4. 

Authors:  F Freymuth
Journal:  EMC Pediatr       Date:  2011-08-10

5.  Otitis media: a genome-wide linkage scan with evidence of susceptibility loci within the 17q12 and 10q22.3 regions.

Authors:  Margaretha L Casselbrant; Ellen M Mandel; Jeesun Jung; Robert E Ferrell; Kathleen Tekely; Jin P Szatkiewicz; Amrita Ray; Daniel E Weeks
Journal:  BMC Med Genet       Date:  2009-09-03       Impact factor: 2.103

6.  Human bocavirus and rhino-enteroviruses in childhood otitis media with effusion.

Authors:  Szilárd Rezes; Maria Söderlund-Venermo; Merja Roivainen; Kaisa Kemppainen; Zsolt Szabó; István Sziklai; Anne Pitkäranta
Journal:  J Clin Virol       Date:  2009-09-06       Impact factor: 3.168

Review 7.  Prevention of otitis media caused by viral upper respiratory tract infection: vaccines, antivirals, and other approaches.

Authors:  William J Doyle; Cuneyt M Alper
Journal:  Curr Allergy Asthma Rep       Date:  2003-07       Impact factor: 4.806

8.  Middle Ear Viral Load Considerations in the COVID-19 Era: A Systematic Review.

Authors:  Jeffrey Liaw; Robert Saadi; Vijay A Patel; Huseyin Isildak
Journal:  Otol Neurotol       Date:  2021-02-01       Impact factor: 2.311

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.